1. Home
  2. PNRG vs ZNTL Comparison

PNRG vs ZNTL Comparison

Compare PNRG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PNRG

PrimeEnergy Resources Corporation

HOLD

Current Price

$176.31

Market Cap

299.2M

Sector

Energy

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$4.85

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNRG
ZNTL
Founded
1973
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
299.2M
289.0M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
PNRG
ZNTL
Price
$176.31
$4.85
Analyst Decision
Hold
Buy
Analyst Count
1
5
Target Price
$160.00
$6.60
AVG Volume (30 Days)
51.8K
1.4M
Earning Date
04-16-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.03
EPS
1.82
N/A
Revenue
$189,052,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.18
N/A
P/E Ratio
$98.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$126.40
$1.21
52 Week High
$278.90
$6.95

Technical Indicators

Market Signals
Indicator
PNRG
ZNTL
Relative Strength Index (RSI) 44.84 63.12
Support Level $160.07 $3.53
Resistance Level $187.50 $5.11
Average True Range (ATR) 8.98 0.42
MACD 2.68 0.08
Stochastic Oscillator 56.72 82.81

Price Performance

Historical Comparison
PNRG
ZNTL

About PNRG PrimeEnergy Resources Corporation

PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: